Skip to main content
Premium Trial:

Request an Annual Quote

VolitionRx Eyes $1.5M Financing Round for Clinical Trials of Nucleosome-based Tests

NEW YORK (GenomeWeb News) – Cancer diagnostics firm VolitionRx has raised $595,000 toward a targeted $1.5 million round, it said in a document filed with the US Securities and Exchange Commission.

In an e-mail to GenomeWeb Daily News, a company spokesperson said the funding will go toward ongoing trials for its NuQ technology, including clinical trials announced late last month with Hvidovre Hospital in Denmark for colorectal cancer.

Investors in the round consisted of individual investors. The company has raised a total of $1.5 million in 2013 and about $6.0 million since its founding in late 2010.

In May 2012, the Singapore-based firm raised $1.2 million to fund clinical trials for its first NuQ test kits, which are blood-based diagnostic tests based on VolitionRx’s Nucleosomics technology. The technology detects and measures nucleosomes in the bloodstream.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.